Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Mr. Adam K. Simpson |
IPO Date | July 29, 2021 |
Location | United States |
Headquarters | 1616 Eastlake Avenue East, Seattle, WA, United States, 98102 |
Employees | 60 |
Sector | Healthcare |
Industry | Biotechnology |
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
NA
NA
NA
NA
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email